Evidence map›Paper›PMID 37457228›Full record

ArticleNeuro-oncology practice2023

Practice variation in re-resection for recurrent glioblastoma: A nationwide survey among Dutch neuro-oncology specialists.

Mark P van Opijnen, Filip Y F de Vos, Rob J A Nabuurs, Tom J Snijders, Rishi D S Nandoe Tewarie, Walter Taal, Joost J C Verhoeff, Jacobus J M van der Hoeven, Marike L D Broekman

Open access · bronzeAbstract read
In one paragraph

Article in Neuro-oncology practice, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Mark P van OpijnenDepartment of Neurosurgery, Haaglanden Medical Center, The Hague, The Netherlands.ORCID https://orcid.org/0000-0002-2400-4626
Filip Y F de VosDepartment of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.ORCID https://orcid.org/0000-0002-9082-5991
Rob J A NabuursDepartment of Neurosurgery, Haaglanden Medical Center, The Hague, The Netherlands.
Tom J SnijdersDepartment of Neurology and Neurosurgery, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht, The Netherlands.ORCID https://orcid.org/0000-0003-0857-081X
Rishi D S Nandoe TewarieDepartment of Neurosurgery, Haaglanden Medical Center, The Hague, The Netherlands.ORCID https://orcid.org/0000-0003-1697-8428
Walter TaalDepartment of Neurology, Brain Tumor Center, Erasmus MC Cancer Institute, Erasmus MC University Medical Center, Rotterdam, The Netherlands.ORCID https://orcid.org/0000-0002-5530-7259
Joost J C VerhoeffDepartment of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.ORCID https://orcid.org/0000-0001-9673-0793
Jacobus J M van der HoevenHartwig Medical Foundation, Amsterdam, The Netherlands.ORCID https://orcid.org/0000-0003-1117-1959
Marike L D BroekmanDepartment of Neurosurgery, Haaglanden Medical Center, The Hague, The Netherlands.ORCID https://orcid.org/0000-0002-0226-0119
University Medical Center Utrecht · NLLeiden University Medical Center · NLMedisch Centrum Haaglanden · NLErasmus MC Cancer Institute · NLHartwig Medical Foundation · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Despite current best treatment options, a glioblastoma almost inevitably recurs after primary treatment. However, in the absence of clear evidence, current guidelines on recurrent glioblastoma are not well-defined. Re-resection is one of the possible treatment modalities, though it can be challenging to identify those patients who will benefit. Therefore, treatment decisions are made based on multidisciplinary discussions. This study aimed to investigate the current practice variation between neuro-oncology specialists. Methods: In this nationwide study among Dutch neuro-oncology specialists, we surveyed possible practice variation. Via an online survey, 4 anonymized recurrent glioblastoma cases were presented to neurosurgeons, neuro-oncologists, medical oncologists, and radiation oncologists in The Netherlands using a standardized questionnaire on whether and why they would recommend a re-resection or not. The results were used to provide a qualitative analysis of the current practice in The Netherlands. Results: The survey was filled out by 56 respondents, of which 15 (27%) were neurosurgeons, 26 (46%) neuro-oncologists, 2 (4%) medical oncologists, and 13 (23%) radiation oncologists. In 2 of the 4 cases, there appeared to be clinical equipoise. Overall, neurosurgeons tended to recommend re-resection more frequently compared to the other specialists. Neurosurgeons and radiation oncologists showed opposite recommendations in 2 cases. Conclusions: This study showed that re-resection of recurrent glioblastoma is subject to practice variation both between and within neuro-oncology specialties. In the absence of unambiguous guidelines, we observed a relationship between preferred practice and specialty. Reduction of this practice variation is important; to achieve this, adequate prospective studies are essential.

Indexed as

Glioblastomapractice variationrecurrencere-resectionsurvey

Identifiers

PMID37457228
PMCPMC10346413
OpenAlexW4324149269

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.